ZD0473 treatment in lung cancer: An overview of the clinical trial results

J. Treat, J. Schiller, E. Quoix, A. Mauer, M. Edelman, M. Modiano, P. Bonomi, R. Ramlau, E. Lemarie

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Three open-label, non-comparative, multicentre Phase II trials have examined the efficacy and tolerability of ZD0473 as first-and second-line therapy in non-small-cell lung cancer (NSCLC) patients and second-line therapy in small-cell lung cancer (SCLC) patients. Patients with second-line NSCLC or SCLC were evaluated as either platinum-sensitive or -resistant, based upon their time to relapse/progression after platinum-based therapy. First-line NSCLC patients (n = 18) received a total of 60 treatment cycles (median number per patient 2.5) whilst second-line NSCLC (n = 50) and SCLC (n = 48) patients both received a total of 127 treatment cycles (median number per patient 2.0). Grade 3/4 anaemia, neutropenia and thrombocytopenia was observed in: 38.8%, 22.2% and 27.7% of first-line NSCLC patients; 12.0%, 24.0% and 50% of second-line NSCLC patients; and 10.4%, 25.0% and 47.9% of second-line SCLC patients, respectively. The most common grade 3/4 non-haematological toxicities in all three trials were lethargy and dyspnoea. No clinically significant oto-, nephro- or neurotoxicity was observed. The first-line treatment of NSCLC produced an overall response rate (OR) of 6.3%. No OR was seen after second-line treatment of NSCLC, while ORs of 15.4% and 8.3% were seen in the platinum-resistant and -sensitive second-line SCLC patients, respectively.

Original languageEnglish (US)
JournalEuropean Journal of Cancer
Volume38
Issue numberSUPPL. 8
StatePublished - 2002

Fingerprint

Meta-Analysis
Lung Neoplasms
Non-Small Cell Lung Carcinoma
Small Cell Lung Carcinoma
Platinum
Therapeutics
amminedichloro(2-methylpyridine)platinum(II)
Lethargy
Neutropenia
Thrombocytopenia
Dyspnea
Anemia
Recurrence

Keywords

  • Lung cancer
  • NSCLC
  • Platinum-resistant
  • Platinum-sensitive
  • SCLC
  • ZD0473

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Treat, J., Schiller, J., Quoix, E., Mauer, A., Edelman, M., Modiano, M., ... Lemarie, E. (2002). ZD0473 treatment in lung cancer: An overview of the clinical trial results. European Journal of Cancer, 38(SUPPL. 8).

ZD0473 treatment in lung cancer : An overview of the clinical trial results. / Treat, J.; Schiller, J.; Quoix, E.; Mauer, A.; Edelman, M.; Modiano, M.; Bonomi, P.; Ramlau, R.; Lemarie, E.

In: European Journal of Cancer, Vol. 38, No. SUPPL. 8, 2002.

Research output: Contribution to journalArticle

Treat, J, Schiller, J, Quoix, E, Mauer, A, Edelman, M, Modiano, M, Bonomi, P, Ramlau, R & Lemarie, E 2002, 'ZD0473 treatment in lung cancer: An overview of the clinical trial results', European Journal of Cancer, vol. 38, no. SUPPL. 8.
Treat J, Schiller J, Quoix E, Mauer A, Edelman M, Modiano M et al. ZD0473 treatment in lung cancer: An overview of the clinical trial results. European Journal of Cancer. 2002;38(SUPPL. 8).
Treat, J. ; Schiller, J. ; Quoix, E. ; Mauer, A. ; Edelman, M. ; Modiano, M. ; Bonomi, P. ; Ramlau, R. ; Lemarie, E. / ZD0473 treatment in lung cancer : An overview of the clinical trial results. In: European Journal of Cancer. 2002 ; Vol. 38, No. SUPPL. 8.
@article{4944d817017146a8a342d203f8ca0e93,
title = "ZD0473 treatment in lung cancer: An overview of the clinical trial results",
abstract = "Three open-label, non-comparative, multicentre Phase II trials have examined the efficacy and tolerability of ZD0473 as first-and second-line therapy in non-small-cell lung cancer (NSCLC) patients and second-line therapy in small-cell lung cancer (SCLC) patients. Patients with second-line NSCLC or SCLC were evaluated as either platinum-sensitive or -resistant, based upon their time to relapse/progression after platinum-based therapy. First-line NSCLC patients (n = 18) received a total of 60 treatment cycles (median number per patient 2.5) whilst second-line NSCLC (n = 50) and SCLC (n = 48) patients both received a total of 127 treatment cycles (median number per patient 2.0). Grade 3/4 anaemia, neutropenia and thrombocytopenia was observed in: 38.8{\%}, 22.2{\%} and 27.7{\%} of first-line NSCLC patients; 12.0{\%}, 24.0{\%} and 50{\%} of second-line NSCLC patients; and 10.4{\%}, 25.0{\%} and 47.9{\%} of second-line SCLC patients, respectively. The most common grade 3/4 non-haematological toxicities in all three trials were lethargy and dyspnoea. No clinically significant oto-, nephro- or neurotoxicity was observed. The first-line treatment of NSCLC produced an overall response rate (OR) of 6.3{\%}. No OR was seen after second-line treatment of NSCLC, while ORs of 15.4{\%} and 8.3{\%} were seen in the platinum-resistant and -sensitive second-line SCLC patients, respectively.",
keywords = "Lung cancer, NSCLC, Platinum-resistant, Platinum-sensitive, SCLC, ZD0473",
author = "J. Treat and J. Schiller and E. Quoix and A. Mauer and M. Edelman and M. Modiano and P. Bonomi and R. Ramlau and E. Lemarie",
year = "2002",
language = "English (US)",
volume = "38",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "SUPPL. 8",

}

TY - JOUR

T1 - ZD0473 treatment in lung cancer

T2 - An overview of the clinical trial results

AU - Treat, J.

AU - Schiller, J.

AU - Quoix, E.

AU - Mauer, A.

AU - Edelman, M.

AU - Modiano, M.

AU - Bonomi, P.

AU - Ramlau, R.

AU - Lemarie, E.

PY - 2002

Y1 - 2002

N2 - Three open-label, non-comparative, multicentre Phase II trials have examined the efficacy and tolerability of ZD0473 as first-and second-line therapy in non-small-cell lung cancer (NSCLC) patients and second-line therapy in small-cell lung cancer (SCLC) patients. Patients with second-line NSCLC or SCLC were evaluated as either platinum-sensitive or -resistant, based upon their time to relapse/progression after platinum-based therapy. First-line NSCLC patients (n = 18) received a total of 60 treatment cycles (median number per patient 2.5) whilst second-line NSCLC (n = 50) and SCLC (n = 48) patients both received a total of 127 treatment cycles (median number per patient 2.0). Grade 3/4 anaemia, neutropenia and thrombocytopenia was observed in: 38.8%, 22.2% and 27.7% of first-line NSCLC patients; 12.0%, 24.0% and 50% of second-line NSCLC patients; and 10.4%, 25.0% and 47.9% of second-line SCLC patients, respectively. The most common grade 3/4 non-haematological toxicities in all three trials were lethargy and dyspnoea. No clinically significant oto-, nephro- or neurotoxicity was observed. The first-line treatment of NSCLC produced an overall response rate (OR) of 6.3%. No OR was seen after second-line treatment of NSCLC, while ORs of 15.4% and 8.3% were seen in the platinum-resistant and -sensitive second-line SCLC patients, respectively.

AB - Three open-label, non-comparative, multicentre Phase II trials have examined the efficacy and tolerability of ZD0473 as first-and second-line therapy in non-small-cell lung cancer (NSCLC) patients and second-line therapy in small-cell lung cancer (SCLC) patients. Patients with second-line NSCLC or SCLC were evaluated as either platinum-sensitive or -resistant, based upon their time to relapse/progression after platinum-based therapy. First-line NSCLC patients (n = 18) received a total of 60 treatment cycles (median number per patient 2.5) whilst second-line NSCLC (n = 50) and SCLC (n = 48) patients both received a total of 127 treatment cycles (median number per patient 2.0). Grade 3/4 anaemia, neutropenia and thrombocytopenia was observed in: 38.8%, 22.2% and 27.7% of first-line NSCLC patients; 12.0%, 24.0% and 50% of second-line NSCLC patients; and 10.4%, 25.0% and 47.9% of second-line SCLC patients, respectively. The most common grade 3/4 non-haematological toxicities in all three trials were lethargy and dyspnoea. No clinically significant oto-, nephro- or neurotoxicity was observed. The first-line treatment of NSCLC produced an overall response rate (OR) of 6.3%. No OR was seen after second-line treatment of NSCLC, while ORs of 15.4% and 8.3% were seen in the platinum-resistant and -sensitive second-line SCLC patients, respectively.

KW - Lung cancer

KW - NSCLC

KW - Platinum-resistant

KW - Platinum-sensitive

KW - SCLC

KW - ZD0473

UR - http://www.scopus.com/inward/record.url?scp=0036983552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036983552&partnerID=8YFLogxK

M3 - Article

C2 - 12645908

AN - SCOPUS:0036983552

VL - 38

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - SUPPL. 8

ER -